12:00 AM
 | 
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Telaprevir: Phase II ongoing

Vertex discontinued the 12-week combination regimen of twice-daily 400 mg VX-222 plus 1,125 mg telaprevir in an ongoing, double-blind, dose-ranging, U.S. Phase II trial after the company said undisclosed pre-defined stopping criteria related to viral breakthrough were met. Vertex said an undisclosed number of patients experienced viral breakthrough. In October, Vertex discontinued the twice-daily 100 mg VX-222 plus telaprevir arm after an undisclosed number of patients experienced viral breakthrough during the first 4 weeks of dosing.

Vertex has...

Read the full 383 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >